Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.1% – Should You Sell?

Eli Lilly and Company (NYSE:LLY)’s share price fell 0.1% during mid-day trading on Friday . The stock traded as low as $784.86 and last traded at $786.28. 955,202 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 2,607,299 shares. The stock had previously closed at $787.22.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Finally, Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Trading Up 1.5 %

The company’s 50 day moving average price is $786.08 and its two-hundred day moving average price is $859.70. The firm has a market cap of $758.87 billion, a PE ratio of 86.42, a P/E/G ratio of 2.99 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.75%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 64.86%.

Eli Lilly and Company declared that its board has approved a stock buyback program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently modified their holdings of the business. Valley Wealth Managers Inc. raised its position in shares of Eli Lilly and Company by 2.8% in the 2nd quarter. Valley Wealth Managers Inc. now owns 1,788 shares of the company’s stock worth $1,619,000 after acquiring an additional 49 shares in the last quarter. Westover Capital Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.4% during the second quarter. Westover Capital Advisors LLC now owns 1,943 shares of the company’s stock valued at $1,759,000 after buying an additional 27 shares during the last quarter. O Neil Global Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $6,370,000. Parallel Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 2.2% in the 2nd quarter. Parallel Advisors LLC now owns 24,273 shares of the company’s stock valued at $21,977,000 after buying an additional 527 shares in the last quarter. Finally, Thoroughbred Financial Services LLC grew its position in shares of Eli Lilly and Company by 35.5% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 18,894 shares of the company’s stock worth $17,106,000 after buying an additional 4,950 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.